718 related articles for article (PubMed ID: 18336608)
1. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
[TBL] [Abstract][Full Text] [Related]
3. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
4. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
Freedland SJ; Partin AW; Epstein JI; Walsh PC
Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
[TBL] [Abstract][Full Text] [Related]
5. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
[TBL] [Abstract][Full Text] [Related]
6. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma.
Eichelberger LE; Cheng L
Cancer; 2004 Jun; 100(12):2573-6. PubMed ID: 15197798
[TBL] [Abstract][Full Text] [Related]
7. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V
Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281
[TBL] [Abstract][Full Text] [Related]
8. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
9. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
10. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens.
Epstein JI
J Urol; 2011 Sep; 186(3):790-7. PubMed ID: 21788055
[TBL] [Abstract][Full Text] [Related]
12. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
Jones TD; Koch MO; Bunde PJ; Cheng L
BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012
[TBL] [Abstract][Full Text] [Related]
13. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.
Ploussard G; Salomon L; Allory Y; Terry S; Vordos D; Hoznek A; Abbou CC; Vacherot F; de la Taille A
BJU Int; 2010 Jul; 106(1):86-90. PubMed ID: 19930177
[TBL] [Abstract][Full Text] [Related]
14. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
[TBL] [Abstract][Full Text] [Related]
15. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.
Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM
BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer.
Ahyai SA; Zacharias M; Isbarn H; Steuber T; Eichelberg C; Köllermann J; Fisch M; Karakiewicz PI; Huland H; Graefen M; Chun FK
BJU Int; 2010 Aug; 106(4):478-83. PubMed ID: 20128781
[TBL] [Abstract][Full Text] [Related]
17. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
18. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
Han M; Walsh PC; Partin AW; Rodriguez R
J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
20. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.
Chun FK; Briganti A; Lebeau T; Fradet V; Steuber T; Walz J; Schlomm T; Eichelberg C; Haese A; Erbersdobler A; McCormack M; Perrotte P; Graefen M; Huland H; Karakiewicz PI
Eur Urol; 2006 Feb; 49(2):273-8; discussion 278-9. PubMed ID: 16413103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
